The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden.

Johan JendleM I BuompensiereA L HolmS de PortuSamuel Joseph Paul MalkinO Cohen

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)

Based on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden.

Keyphrases

healthcare
public health
climate change
mental health
health insurance
risk assessment
social media
health promotion
replacement therapy